CRISPR-like technique offers clues to mimic protective genetic mutations
Using a variation of CRISPR gene editing may be a potential strategy for mimicking the protective effects of a genetic mutation linked to lower cholesterol levels and heart disease risks, according to new mouse research from the Perelman School of Medicine at the University of Pennsylvania published this week in Circulation.
People with naturally occurring mutations that cause a loss of function in the gene for ANGPTL3 have reduced blood triglycerides, LDL cholesterol, and risk of coronary heart disease, with no apparent detrimental consequences to their health. This makes the ANGPTL3 protein an attractive target for new heart disease drugs. Earlier studies at Penn found that single copies of inactivating mutations in ANGPTL3 are found in about one in every 250 people of European heritage; however, people with mutations in both copies of the gene are more rare.
A team led by Kiran Musunuru, MD, PhD, MPH, an associate professor of Cardiovascular Medicine, assessed in a mouse model whether base editing – a variation of CRISPR genome editing that does not require breaks in the double-strand of DNA – might be used in humans one day to introduce mutations into ANGPTL3 to reduce blood lipid levels.
“This proof-of-principle study showed that base-editing of ANGPTL3 is a potential way to permanently treat patients with harmful blood lipid levels,” Musunuru said. “It would be especially useful in patients with a rare condition called homozygous familial hypercholesterolemia, which causes sky-high cholesterol levels and dramatically increased risk of heart attack. They are very difficult to treat with today’s medications, and a one-time CRISPR ‘vaccination’ might be ready to use in these patients within five years.”
The study took a three-part approach. First, the team injected normal mice with the base-editing treatment for the ANGPTL3 gene. After a week, sequencing of the ANGPTL3 target site in liver samples from the mice revealed a median 35 percent editing rate in the target gene and no off-target mutations. In addition, the mean levels of blood lipids were significantly lower in the treated mice by up to 30 percent compared to untreated mice.
Second, the researchers compared mice with the modified ANGPTL3 gene to those injected with a base-editing treatment for another liver gene, PCSK9, for plasma cholesterol and triglycerides. After a week, ANGPTL3 targeting caused a similar reduction in cholesterol but a much greater decline in triglycerides compared to targeting PCSK9. The PCSK9 protein is the target of currently available medications, including evinacumab, which has been shown to reduce cholesterol (but not triglycerides) as well as the risk of heart attack and stroke.
Third, they looked at how base editing of the ANGPTL3 gene performed in a mouse model of homozygous familial hypercholesterolemia (in which knocking out PCSK9 had little effect). After two weeks, the treated mice showed substantially reduced triglycerides (56 percent) and cholesterol (51 percent) compared to untreated mice.
Musunuru’s lab is now preparing to test CRISPR-based treatments against the human ANGPTL3 gene in human liver cells transplanted into mice. This will provide important information on efficacy and safety that will be needed before human trials can move forward.
The Latest on: Gene editing
Priest-Neuroscientist: Embryo Gene-Editing Poses Inescapable Ethical Problems
on July 20, 2018 at 7:37 am
A response to a London-based think tank that called recently for further research into embryonic gene editing. Kevin Jones/CNA/EWTN News LONDON — Genetic editing of human embryos, even in special circ... […]
Genome damage from CRISPR/Cas9 gene editing higher than thought
on July 20, 2018 at 6:56 am
Scientists have discovered that CRISPR/Cas9 gene editing can cause greater genetic damage in cells than was previously thought. This has safety implications for future gene therapies using CRISPR/Cas9 ... […]
Gene Editing Is Coming: Get In Front Of Sangamo Therapeutics's 'Irrational Extrapolation Event'
on July 19, 2018 at 7:19 pm
SGMO's gene editing/therapy data could spark an "irrational extrapolation event." The total addressable market for gene editing/therapy really is this big. And no one believes it. A scenario analysis ... […]
CRISPR gene editing possible without using a virus, scientists say
on July 19, 2018 at 2:01 pm
July 12 (UPI) --Scientists have figured out a way to use genetically reprogram human immune cells without using viruses to insert DNA, as the CRISPR method of gene editing has traditionally required. ... […]
Weird new fruits could hit aisles soon thanks to gene-editing
on July 19, 2018 at 10:16 am
A red-fleshed apple of the Redlove hybrid variety. Unusual fruits such as this could soon become more common thanks to use of technologies such as Crispr. Photograph: Bailey-Cooper Photography/Alamy S... […]
Embryo gene-editing poses inescapable ethical problems, critic says
on July 18, 2018 at 6:08 pm
London, England, Jul 18, 2018 / 07:00 pm (CNA/EWTN News).- Genetic editing of human embryos, even in special circumstances, ignores the complex ethical problems related to creating and destroying huma... […]
New Study Finds Unintended Consequences of CRISPR Gene Editing
on July 18, 2018 at 11:40 am
Scientists and biotechnologists have heralded the CRISPR-Cas9 gene editing system as revolutionary way to edit DNA, like scissors and a glue stick for the genome. But a new study found some potentiall... […]
CRISPR gene editing scissors are less accurate than we thought, but there are fixes
on July 17, 2018 at 6:39 am
CRISPR gene editing technology is revolutionizing medicine and biology. This technique allows scientists to edit DNA with more precision and greater ease than previous gene editing technology. But a n... […]
CRISPR/Cas9 gene editing scissors are less accurate than we thought, but there are fixes
on July 17, 2018 at 4:14 am
We need to know gene editing technology is precise before we try to use it to cure diseases. Credit: www.shutterstock.com CRISPR gene editing technology is revolutionising medicine and biology. This t... […]
CRISPR Therapeutics Stock History: The Rise of the World's Biggest Gene-Editing Biotech
on July 16, 2018 at 10:12 am
How did the biotech rise to the top of the CRISPR gene editing world? Here's the story behind CRISPR Therapeutics and its sizzling stock performance. CRISPR Therapeutics is a biotech that focuses on d... […]
via Google News and Bing News